Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cellsLucie Leveque, Florence Deknuydt, Gilles Bioley, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 2005
A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patientsMaha Ayyoub, Naira E Souleimanian, Emmanuelle Godefroy, et al.
Clinical Immunology (Orlando, Fla.)|July 4, 2006
Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II allelesEmmanuelle Godefroy, Luigi Scotto, Naira E Souleimanian, et al.
Clinical Immunology (Orlando, Fla.)|January 2, 2008
Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ TregsValeria Tosello, Kunle Odunsi, Naira E Souleimanian, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2006
Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individualsEmmanuelle Godefroy, Yu Wang, Naira E Souleimanian, et al.
Molecular Immunology|March 24, 2004
A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopesJ Javier Nino-Vasquez, Gina Allicotti, Eva Borras, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 26, 2002
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populationsYasuhiro Nagata, Satoru Ono, Mitsutoshi Matsuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2009
Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoireGilles Bioley, Christelle Dousset, Alice Yeh, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1Frédérique-Anne Le Gal, Maha Ayyoub, Valérie Dutoit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccineGilles Bioley, Philippe Guillaume, Immanuel Luescher, et al.
Pageof 8